Abstract
The prevalence of lymphoma in primary immunodeficiency cases and autoimmune diseases, as well as on a background of immunodeficiency following organ transplants, is increasing. The lymphoma treatment success rate is known to be a low prognosis. Our study aimed to emphasize the low survival rates in immunodeficient vs. immunocompetent lymphoma patients and also to investigate the effect of rituximab in patients with ataxia telangiectasia and other immunodeficiencies. We summarized the clinical characteristics and treatment results of 17 cases with primary immunodeficiency that developed non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) retrospectively. Seven patients were diagnosed with ataxia-telangiectasia, two with common variable immunodeficiency, two with selective IgA deficiency, one with X-related lymphoproliferative syndrome, one with Wiskott-Aldrich syndrome, one with Epstein-Barr virus-related lymphoproliferative syndrome, one with interleukin-2-inducible T-cell kinase (ITK) deficiency, and one with lymphoma developing after autoimmune lymphoproliferative syndrome (ALPS). One patient underwent a renal transplant. Of the nine males and eight females (aged 3–12 years, median = 7) that developed lymphoma, seven were diagnosed with HL and ten with NHL (seven B-cell, three T-cell). The NHL patients were started on the Berlin-Frankfurt-Münster, POG9317, LMB-96, or R-CHOP treatment protocols with reduced chemotherapy dosages. HL cases were started on the doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and/or cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) protocol, also with modified dosages. Importantly, all seven cases of HL are alive and in remission, while six of the ten NHL patients have died. Primary immunodeficiency is a strong predisposing factor for developing lymphoma. Low treatment success rates relative to other lymphomas and difficulties encountered during treatment indicate that new treatment agents are needed. While some success has been achieved by combining rituximab with lymphoma treatment protocols in B-NHL cases with primary immunodeficiency, the need for new treatment approaches for these patients remains critical.
Similar content being viewed by others
References
Filipovich AH, Heinitz KJ, Robison LL, Frizzera G. The immunodeficiency cancer registry. A research resource. Am J Pediatr Hematol Oncol. 1987;9:183–4.
Elenitoba-Johnson KS, Jaffe ES. Lymphoproliferative disorders associated with congenital immunodeficiencies. Semin Diagn Pathol. 1997;14:35–47.
Filipovich AH, Mathur A, Kamat D, Kersey JH, Shapiro RS. Lymphoproliferative disorders and other tumors complicating immunodeficiency. Immunodeficiency. 1994;5:91–112.
Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 236 patients with ataxia telangiectasia. J Natl Cancer Inst. 1986;77:89–92.
Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P. Incidence of cancer in 98 patients with common variable immunodeficiency. J Clin Immunol. 1987;7:294–301.
Taylor AMR, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood. 1996;87:423–38.
Turvey SE, Bonilla FA, Junker AK. Primary immunodeficiency diseases: a practical guide for clinicians. Postgrad Med J. 2009;85:660–6.
Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev. 2008;22:261–81.
Meyn MS. Chromosome instability syndromes: lessons for carcinogenesis. In Kaston MB, editor. Genetic instability and tumorigenesis. Current topics in microbiology and immunology; 1997. pp. 71–148.
Green AJ, Yates JR, Taylor AM, Biggs P, McGuire GM, McConville CM, et al. Severe microcephaly with normal intellectual development: the Nijmegen breakage syndrome. Arch Dis Child. 1995;73:431–4.
Overberg-Schmidt U, Wegner RD, Baumgarten E, Günther A, Ebell W, Stein H, et al. Low-grade non-Hodgkin’s lymphoma after high-grade non-Hodgkin’s lymphoma in a child with ataxia telangiectasia. Cancer. 1994;73:1522–5.
Janic D, Dokmanovic L, Jovanovic N, Lazic J. T-cell acute lymphoblastic leukemia in a child with ataxia-telangiectasia: case report. J Pediatr Hematol Oncol. 2007;29:713–5.
Sharma LM, Kashyap R, Gupta S, Bhargava M. B-cell acute lymphoblastic leukemia in a child with ataxia-telangiectasia. Pediatr Hematol Oncol. 2008;5:473–6.
Kastan MB. DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A Clowes Memorial Award Lecture. Mol Cancer Res. 2008;6:517–24.
Hecht F, Hecht BK. Chromosome changes connect immunodeficiency and cancer in ataxia-telangiectasia. Am J Pediatr Hematol Oncol. 1987;9:185–8.
Seidemann K, Henze G, Beck JD, Sauerbrey A, Kühl J, Mann G, et al. Non-Hodgkin’s lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol. 2000;11:141–5.
Maclean KH, Kastan MB, Cleveland JL. Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. Mol Cancer Res. 2007;5:705–11.
Shield JPH, Strobel S, Levinsky RJ, Morgan G. Immunodeficiency presenting as hypergammaglobulinemia with IgG2 subclass deficiency. Lancet. 1992;340:448–51.
Buckley RH. Breakthroughs in the understanding and therapy of primary immunodeficiency. Pediatr Clin North Am. 1994;41:665–90.
Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. 1995;38:471–8.
Sumegi J, Huang D, Lanyi A, Davis JD, Seemayer TA, Maeda A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96:3118–25.
Seidemann K, Tiemann M, Henze G, Sauerbrey A, Müller S, Reiter A. Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials. Med Pediatr Oncol. 1999;33:536–44.
Sandoval C, Swift M. Treatment of lymphoid malignancies in patients with ataxia telangiectasia. Med Pediatr Oncol. 1998;31:491–7.
Shabbat S, Aharoni J, Sarid L, Ben-Harush M, Kapelushnik J. Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and non-Hodgkin lymphoma. Pediatr Blood Cancer. 2009;52:664–6.
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1.
Murphy SB. Classification, staging and results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7:332–9.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.
Kropshofer G, Wehl G, Klein-Franke A, Herbrecht R, Tilly H, Bouabdallah R, et al. B-cell lymphoma in a girl with ataxia telangiectasia (A-T) treated with rituximab monotherapy. Pediatr Blood Cancer. 2006;46:528–9.
Rossi G, Zecca M, Marchi A, de Stefano P, Sammarchi L, Locatelli F. Modified CHOP-chemotherapy plus rituximab for diffuse large B-cell lymphoma complicating ataxia-telangiectasia. Br J Haematol. 2003;120:369–71.
Sandlund JT, Hudson MM, Kennedy W, Onciu M, Kastan MB. Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies. Pediatr Blood Cancer. 2014;61:360–2.
Perry III GS, Spector BD, Schuman LM, Mandel JS, Anderson VE, McHugh RB, et al. The Wiskott-Aldrich syndrome in the United States and Canada (1892–1979). J Pediatr. 1980;97:72–8.
Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994;78:635–44.
Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia RM. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood. 2009;113:6288–95.
Staub E, Groene J, Heinze M, Mennerich D, Roepcke S, Klaman I, et al. An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. J Mol Med. 2009;87:633–44.
Du S, Scuderi R, Malicki DM, Willert J, Bastian J, Weidner N. Hodgkin’s and non-Hodgkin’s lymphomas occurring in two brothers with Wiskott-Aldrich syndrome and review of the literature. Pediatr Dev Pathol. 2011;14:64–70.
Pasic S, Vujic D, Djuricic S, Jevtic D, Grujic B. Burkitt lymphoma-induced ileocolic intussusceptions in Wiskott-Aldrich syndrome. J Pediatr Hematol Oncol. 2006;28:48–50.
Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P. Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol. 1987;7:294–9.
Emir S, Vezir E, Azkur D, Demir HA, Metin A. Characteristics of children with non-Hodgkin lymphoma associated with primary immune deficiency diseases: descriptions of five patients. Pediatr Hematol Oncol. 2013;30:544–53.
Riex-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347–9.
Bleesing JJ. Autoimmune lymphoproliferative syndrome (ALPS). Curr Pharm Des. 2003;9:265–78.
Clementi R, Dagna L, Dianzani U, Dupré L, Dianzani I, Ponzoni M, et al. Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. N Engl J Med. 2004;351:1419–24.
Poppema S, Maggio E, van den Berg A. Development of lymphoma in autoimmune lymphoproliferative syndrome (ALPS) and its relationship to Fas gene mutations. Leuk Lymphoma. 2004;45:423–31.
Rao VK, Straus SE. Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology. 2006;11:15–23.
Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol. 1997;14:8–14.
Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21:1352–8.
Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK, et al. B-cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transpl. 1999;23:251–8.
Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633–9.
Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–16.
Socie G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18:348–57.
Robison LL, Stoker V, Frizzera G, Heinitz K, Meadows AT, Filipovich AH. Hodgkin’s disease in pediatric patients with naturally occurring immunodeficiency. Am J Pediatr Hematol Oncol. 1987;9:189–92.
Crnkovich MJ, Leopold K, Hoppe RT, Mauch PM. Stage I to IIB Hodgkin’s disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol. 1987;5:1041–9.
Sandoval C, Swift M. Hodgkin disease in ataxia-telangiectasia patients with poor outcomes. Med Pediatr Oncol. 2003;40:162–6.
Niehues T, Schellong G, Dörffel W, Bucsky P, Mann G, Körholz D, et al. Immunodeficiency and Hodgkin’s disease: treatment and outcome in the DAL HD78-90 and GPOH HD95 studies. Klin Padiatr. 2003;215:315–20.
Meister MT, Voss S, Schwabe D. Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab. Pediatr Blood Cancer. 2015;62:2018–20.
Duraisingham SS, Buckland M, Dempster J, Lorenzo L, Grigoriadou S, Longhurst HJ. Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. PLoS One. 2014;9:e100324.
Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145:709–27.
Wobser M, Kerstan A, Kneitz H, Goebeler M, Kunzmann V, Rosenwald A, et al. Primary cutaneous marginal zone lymphoma with sequential development of nodal marginal zone lymphoma in a patient with selective immunoglobulin A deficiency. J Cutan Pathol. 2013;40:1035–41.
Ott MM, Ott G, Klinker H, Trunk MJ, Katzenberger T, Müller-Hermelink HK. Abdominal T-cell non-Hodgkin’s lymphoma of the gamma/delta type in a patient with selective immunoglobulin A deficiency. Am J Surg Pathol. 1998;22:500–6.
Chen Y, Jin M, Zhao W, Li S, Wang X, Cai S, et al. DICER1-negative pleuropulmonary blastoma in a patient with selective IgA deficiency. Pediatr Blood Cancer. 2016;63:757–8.
Ghosh S, Bienemann K, Boztug K, Borkhardt A. Interleukin-2-inducible T-cell kinase (ITK) deficiency—clinical and molecular aspects. J Clin Immunol. 2014;34:892–9.
Gross TG, Filipovich AH, Conley ME, Pracher E, Schmiegelow K, Verdirame JD, et al. Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. Bone Marrow Transpl. 1996;17:741–4.
Zhu J, Zhang Y, Zhen ZJ, Chen Y, Wang J, Cai RQ, et al. Lymphoma and cerebral vasculitis in association with X-linked lymphoproliferative disease. Chin J Cancer. 2013;32:673.
Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, Heath PT, Steward CG, Smith O, O’Meara A, Kerrigan H, Mahlaoui N, Cavazzana-Calvo M, Fischer A, Moshous D, Blanche S, Pachlopnik Schmid J, Latour S, de Saint-Basile G, Albert M, Notheis G, Rieber N, Strahm B, Ritterbusch H, Lankester A, Hartwig NG, Meyts I, Plebani A, Soresina A, Finocchi A, Pignata C, Cirillo E, Bonanomi S, Peters C, Kalwak K, Pasic S, Sedlacek P, Jazbec J, Kanegane H, Nichols KE, Hanson IC, Kapoor N, Haddad E, Cowan M, Choo S, Smart J, Arkwright PD, Gaspar HB. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117:53–62.
Authors’ Contributions
HGT and NT designed the project. HGT wrote the manuscript. AI, FD, and NT reviewed the manuscript. The remaining authors provided clinical samples and data.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Tanyildiz, H.G., Dincaslan, H., Yavuz, G. et al. Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center. J Clin Immunol 36, 667–676 (2016). https://doi.org/10.1007/s10875-016-0324-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-016-0324-z